Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis

Cell Research

Volumn 13, Issue 5, 2003, Pages 319-333

  Yu, Jian ^a   Zhang, Hong Yu ^a   Ma, Zhen Zhong ^a   Lu, Wei ^b   Wang, Yi Fei ^b   Zhu, JingDe ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI UNIVERSITY   (China)

Author keywords

Concordant behaviors of methylation; Methylation specific PCR; Promoter CpG island

Indexed keywords

CHICKEN ANEMIA VIRUS;

PROTEIN P16INK4A; TUMOR PROTEIN;

ARTICLE; CPG ISLAND; DNA METHYLATION; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; ONCOGENE; PATHOLOGY; POLYMERASE CHAIN REACTION;

CARCINOMA, HEPATOCELLULAR; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; HUMANS; LIVER NEOPLASMS; NEOPLASM PROTEINS; ONCOGENES; POLYMERASE CHAIN REACTION;

EID: 1542322897     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/sj.cr.7290177     Document Type: Article

References (66)

1. Ferlay J, F Bray, P Pisani and D M Parkin. GOBOCAB 2000 Cancer Incidence, Mortality and Prevalence Worldwide,. Lyon: IARC Scienctific Publications, IARC Press, 2001
2. Parkin D, P Pisani and J Ferlay. Global cancer statistics. CA Cancer J. Clin., 1999; 49:33-64.
3. Cancer Incidence and Mortality in China, 1993-1997 (Selected Cities and Counties). Beijing: China Publishing House of Medical Sciences and Technologies, 1998
4. Feitelson M A, B Sun, N L Satiroglu Tufan, J Liu, J Pan and Z Lian. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002; 21(16):2593-604.
5. Kim J W and X W Wang. Gene expression profiling of preneoplastic liver disease and liver cancer: a new era for improved early detection and treatment of these deadly diseases? Carcinogenesis 2003; 24(3):363-9.
6. Wang X W, S P Hussain, T I Huo, et al. Molecular pathogenesis of human hepatocellular carcinoma. Toxicology 2002; 181-182:43-7.
7. Baylin S and T H Bestor. Altered methylation patterns in cancer cell genomes: cause or consequence? Cancer Cell 2002; 1(4):299-305.
8. Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncol 2003; 4(6):351-8.
9. Esteller M and J G Herman. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 2002; 196(1):1-7.
10. Jones P A and D Takai. The role of DNA methylation in mammalian epigenetics. Science 2001; 293(5532):1068-70.
11. Jaenisch R and A Bird. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003; 33 Suppl:245-54.
12. Jones P A. Epigenetics in carcinogenesis and cancer prevention. Ann N Y Acad Sci 2003; 983:213-9.
13. Geiman T M and K D Robertson. Chromatin remodeling, histone modifications, and DNA methylation-how does it all fit together? J Cell Biochem 2002; 87(2):117-25.
14. Feninberg A. Cancer epigenetics takes center stage. Proc. Natl. Acad. Sci. U S.A. 2001; 98(2):392-4.
15. Eden A, F Gaudet, A Waghmare and R Jaenisch. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003; 300(5618):455.
16. Gaudet F, J G Hodgson, A Eden, et al. Induction of tumors in mice by genomic hypomethylation. Science 2003; 300(5618):489-92.
17. Chen R Z, U Pettersson, C Beard, L Jackson-Grusby and R Jaenisch. DNA hypomethylation leads to elevated mutation rates. Nature 1998; 395(6697):89-93.
18. Esteller M, M F Fraga, M Guo, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 2001; 10(26):3001-7.
19. Zochbauer-Muller S, K M Fong, A K Virmani, J Geradts, A F Gazdar and J D Minna. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001; 61 (1):249-55.
20. Rosas S L, W Koch, M G da Costa Carvalho, et al. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 2001; 61 (3):939-42.
21. Foster S A, D J Wong, M T Barrett and D A Galloway. Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol Cell Biol 1998; 18(4):1793-801.
22. Cui H, P Onyango, S Brandenburg, Y Wu, C L Hsieh and A P Feinberg. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res 2002; 62(22):6442-6.
23. Cho B, H Lee, S Jeong, et al. Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. Biochem Biophys Res Commun 2003; 307(1):52-63.
24. Hattori M, H Sakamoto, K Satoh and T Yamamoto. DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. Cancer Lett 2001; 169(2):155-64.
25. Hoare S F, L A Bryce, G B Wisman, et al. Lack of telomerase RNA gene hTERC expression in alternative lengthening of telomeres cells is associated with methylation of the hTERC promoter. Cancer Res 2001; 61(1):27-32.
26. Toyota M, N Ahuja, M Ohe-Toyota, J G Herman, S B Baylin and J P Issa. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999; 96(15):8681-6.
27. Yu J, M Ni, J Xu, et al. Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer 2002; 2(1):29.
28. Liver Cancer Study Group of Japan. TNM classification for hepatocellular carcinoma by Liver Cancer Study group. World J Surg 1989; 13:212.
29. Miller A J. Subset Selection in Regression. New York Champman and Hall 1990.
30. Liu Q, Wang, W, & eds. Liver Cancer. Beijing: People's Medical Publishing House, 2000
31. Mou D C, S L Cai, J R Peng, et al. Evaluation of MAGE-1 and MAGE-3 as tumour-specific markers to detect blood dissemination of hepatocellular carcinoma cells. Br J Cancer 2002; 86(1):110-6.
32. Yin H and K Blanchard. DNA methylation represses the expression of the human erythopoietin gene by two diffferent mechanisms. Blood 2000; 95(1):111-9.
33. Sauter P and P Matthias. Coactivator OBF-1 makes selective contacts with both the POU-specific domain and the POU homeodomain and acts as a molecular clamp on DNA. Mol Cell Biol 1998; 18(12):7397-409.
34. Iwamoto S, D A Withers, K Handa and S Hakomori. Deletion of A-antigen in a human cancer cell line is associated with reduced promoter activity of CBF/NF-Y binding region, and possibly with enhanced DNA methylation of A transferase promoter. Glycoconj J 1999; 16(10):659-66.
35. Chen B, P Dias, J J Jenkins, 3rd, V H Savell and D M Parham. Methylation alterations of the MyoD1 upstream region are predictive of subclassification of human rhabdomyosarcomas. Am J Pathol 1998; 152(4):1071-9.
36. Hutchins A S, A C Mullen, H W Lee, et al. Gene silencing quantitatively controls the function of a developmental trans-activator. Mol Cell 2002; 10(1):81-91.
37. Reeben M, S Myohanen, M Saarma and H Prydz. Sequencing of the rat light neurofilament promoter reveals differences in methylation between expressing and non-expressing cell lines, but not tissues. Gene 1995; 157(1-2):325-9.
38. Kibel A S, M Christopher, D A Faith, G S Bova, P J Goodfellow and W B Isaacs. Methylation and mutational analysis of p27 (kip1) in prostate carcinoma. Prostate 2001; 48(4):248-53.
39. Li Y, H Nagai, T Ohno, et al. Aberrant DNA methylation of p57 (KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood 2002; 100(7):2572-7.
40. Watanabe T, H Huang, M Nakamura, et al. Methylation of the p73 gene in gliomas. Acta Neuropathol (Berl) 2002; 104(4):357-62.
41. Laux D L, L M Curran, W V Welshons, D B Lubahn and T H Huang. Hypermethylation of the Wilms' tumor suppressor gene CpG island in human breast carcinomas. Breast Cancer Res Treat 1999; 56(1):35-43.
42. Wang S, T Hashemi, S Fried, A L Clemmons and B E Hawes. Differential intracellular signaling of the GalR1 and GalR2 galanin receptor subtypes. Biochemistry 1998; 37(19):6711-7.
43. Usmani B A, R Shen, M Janeczko, et al. Methylation of the neutral endopeptidase gene promoter in human prostate cancers. Clin Cancer Res 2000; 6(5):1664-70.
44. Venkataraman G M, M Yatin, R Marcinek and K B Ain. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. J Clin Endocrinol Metab 1999; 84(7):2449-57.
45. Cui J, L R Rohr, G Swanson, V O Speights, T Maxwell and AR Brothman. Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate 2001; 46(3):249-56.
46. Toyota M, C Ho, N Ahuja, et al. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 1999; 59(10):2307-12.
47. Sasaki M, Y Tanaka, G Perinchery, et al. Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst 2002; 94(5):384-90.
48. Muller C, C Readhead, S Diederichs, et al. Methylation of the cyclin A1 promoter correlates with gene silencing in somatic cell lines, while tissue-specific expression of cyclin A1 is methylation independent. Mol Cell Biol 2000; 20(9):3316-29.
49. Rachmilewitz E A. The role of methylation in CML. Przegl Lek 2000; 57 Suppl 1:25-6.
50. Habuchi T, M Luscombe, P A Elder and M A Knowles. Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. Genomics 1998; 48(3):277-88.
51. Ghoshal K, S Majumder, Z Li, X Dong and S T Jacob. Suppression of metallothionein gene expression in a rat hepatoma because of promoter-specific DNA methylation. J Biol Chem 2000; 275(1):539-47.
52. Yuasa Y. DNA methylation in cancer and ageing. Mech Ageing Dev 2002; 123(12):1649-54.
53. Richardson B. Impact of aging on DNA methylation. Ageing Res Rev 2003; 2(3):245-61.
54. Yamanaka M, M Watanabe, Y Yamada. et al. Altered methylation of multiple genes in carcinogenesis of the prostate. Int J Cancer 2003; 106(3):382-7.
55. Tavian D, G De Petro, A Pitozzi, N Portolani, S M Giulini and S Barlati. Androgen receptor mRNA under-expression in poorly differentiated human hepatocellular carcinoma. Histol Histopathol 2002; 17(4):1113-9.
56. Dong S, J C Pang, J Hu, L F Zhou and H K Ng. Transcriptional inactivation of TP73 expression in oligodendroglial tumors. Int J Cancer 2002; 98(3):370-5.
57. Loiseau H, J Arsaut and J Demotes-Mainard. p73 gene transcripts in human brain tumors: overexpression and altered splicing in ependymomas. Neurosci Lett 1999; 263(2-3):173-6.
58. Satoh Y, T Nakagawachi, H Nakadate, et al. Significant Reduction of WT1 Gene Expression, Possibly Due to Epigenetic Alteration in Wilms' Tumor. J Biochem (Tokyo) 2003; 133(3):303-8.
59. Tomita Y V Bilim, N Hara, T Kasahara and K Takahashi. Role of IRF-1 and caspase-7 in IFN-gamma enhancement of Fas-mediated apoptosis in ACHN renal cell carcinoma cells. Int J Cancer 2003; 104(4):400-8.
60. Detjen K M, D Murphy, M Welzel, K Farwig, B Wiedenmann and S Rosewicz. Downregulation of p21(waf/cip-1) mediates apoptosis of human hepatocellular carcinoma cells in response to interferon-gamma. Exp Cell Res 2003; 282(2):78-89.
61. Lu R, W C Au, W S Yeow, N Hageman and P M Pitha. Regulation of the promoter activity of interferon regulatory factor-7 gene. Activation by interferon snd silencing by hyperme-thylation. J Biol Chem 2000; 275(41):31805-12.
62. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002; 21(35):5400-13.
63. Su Q and P Bannasch. Relevance of hepatic preneoplasia for human hepatocarcinogenesis. Toxicol Pathol 2003; 31(1):126-33.
64. Kopp-Schneider A. Biostatistical evaluation of focal hepatic preneoplasia. Toxicol Pathol 2003; 31(1):121-5.
65. Baylin S B and J G Herman. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16 (4):168-74.
66. Bestor T H. Unanswered questions about the role of promoter methylation in carcinogenesis. Ann N Y Acad Sci 2003; 983:22-7.